Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

PFIZER REPORTS FIRST-QUARTER 2018 RESULTS

Business Wire May 1, 2018

15 Stocks To Watch For May 1, 2018

Benzinga.com  May 1, 2018

Upcoming Earnings: Tech Giant Apple Reports After Tuesday's Close

Benzinga.com  April 30, 2018

Busy Week Begins With McDonald's Beating Estimates; Fed Meeting, Jobs Data Loom

Benzinga.com  April 30, 2018

Upcoming Earnings: McDonald's Reports On Monday As It Continues On New Growth Plan

Benzinga.com  April 27, 2018

Pfizer Hosts Annual Meeting of Shareholders

Business Wire April 26, 2018

Earnings Preview: Checking In On The Automakers With Reports From Ford And GM Coming Up

Benzinga.com  April 24, 2018

Top Ideas From The 2018 Sohn Conference: Box, Bitcoin, Facebook, Palo Alto And More

Benzinga.com  April 23, 2018

Pfizer Granted FDA Breakthrough Therapy Designation for TRUMENBA® (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Children Ages 1 to 9 Years

Business Wire April 23, 2018

Pfizer Provides Update on Proposed Trastuzumab Biosimilar

Business Wire April 23, 2018

MYLOTARG™ Approved In The EU For The Treatment Of Previously Untreated, De Novo, CD33-positive Acute Myeloid Leukemia In Combination With Chemotherapy

Business Wire April 23, 2018

Pfizer Invites Public to Listen to Webcast of April 26 Annual Meeting of Shareholders

Business Wire April 19, 2018

A.M. Best Affirms Credit Ratings of Blue Whale Re Ltd.

Business Wire April 17, 2018

U.S. FDA Approves Pfizer’s BOSULIF® (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML)

Business Wire December 19, 2017

Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts

Business Wire December 19, 2017

Pfizer Declares First-Quarter 2018 Dividend

Business Wire December 18, 2017

Pfizer Inc. Announces Expiration and Results of its Private Exchange Offer for its 6.500 per cent. Notes due 2038 and Related Tender Offer

Business Wire December 15, 2017

Pfizer Announces FDA Approval of XELJANZ® (tofacitinib) and XELJANZ® XR for the Treatment of Active Psoriatic Arthritis

Business Wire December 14, 2017

Pfizer Inc. Announces Pricing Terms of Private Exchange Offer for its 6.500 per cent. Notes due 2038 Open to Certain Investors and Related Tender Offer Open to All Investors

Business Wire December 14, 2017

Pfizer Initiates Phase 3 Program for PF-04965842, a JAK1 Inhibitor in Development for Moderate-to-Severe Atopic Dermatitis

Business Wire December 14, 2017